Literature DB >> 8124716

Identification and sequence of an accessory factor required for activation of the human interferon gamma receptor.

J Soh1, R J Donnelly, S Kotenko, T M Mariano, J R Cook, N Wang, S Emanuel, B Schwartz, T Miki, S Pestka.   

Abstract

Human chromosomes 6 and 21 are both necessary to confer sensitivity to human interferon gamma (Hu-IFN-gamma), as measured by induction of class I human leukocyte antigen (HLA) and protection against encephalomyocarditis virus (EMCV) infection. Whereas human chromosome 6 encodes the Hu-IFN-gamma receptor, human chromosome 21 encodes accessory factors for generating biological activity through the Hu-IFN-gamma receptor. Probes from a genomic clone were used to identity cDNA clones expressing a species-specific accessory factor. These cDNA clones are able to substitute for human chromosome 21 to reconstitute the Hu-IFN-gamma receptor-mediated induction of class I HLA antigens. However, the factor encoded by the cDNA does not confer full antiviral protection against EMCV, confirming that an additional factor encoded on human chromosome 21 is required for reconstitution of antiviral activity against EMCV. We conclude that this accessory factor belongs to a family of such accessory factors responsible for different actions of IFN-gamma.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8124716     DOI: 10.1016/0092-8674(94)90354-9

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  43 in total

1.  Characterization of a soluble ternary complex formed between human interferon-beta-1a and its receptor chains.

Authors:  R M Arduini; K L Strauch; L A Runkel; M M Carlson; X Hronowski; S F Foley; C N Young; W Cheng; P S Hochman; D P Baker
Journal:  Protein Sci       Date:  1999-09       Impact factor: 6.725

2.  Human cytomegalovirus harbors its own unique IL-10 homolog (cmvIL-10).

Authors:  S V Kotenko; S Saccani; L S Izotova; O V Mirochnitchenko; S Pestka
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-15       Impact factor: 11.205

3.  IFN consensus sequence binding protein potentiates STAT1-dependent activation of IFNgamma-responsive promoters in macrophages.

Authors:  C Contursi; I M Wang; L Gabriele; M Gadina; J O'Shea; H C Morse; K Ozato
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

4.  The intracellular domain of interferon-alpha receptor 2c (IFN-alphaR2c) chain is responsible for Stat activation.

Authors:  S V Kotenko; L S Izotova; O V Mirochnitchenko; C Lee; S Pestka
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-27       Impact factor: 11.205

5.  Identification and functional characterization of a second chain of the interleukin-10 receptor complex.

Authors:  S V Kotenko; C D Krause; L S Izotova; B P Pollack; W Wu; S Pestka
Journal:  EMBO J       Date:  1997-10-01       Impact factor: 11.598

6.  Targeted disruption of the interferon-gamma receptor 2 gene results in severe immune defects in mice.

Authors:  B Lu; C Ebensperger; Z Dembic; Y Wang; M Kvatyuk; T Lu; R L Coffman; S Pestka; P B Rothman
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-07       Impact factor: 11.205

7.  Crystallization and preliminary X-ray analysis of a 1:1 complex between a designed monomeric interferon-gamma and its soluble receptor.

Authors:  M Randal; A A Kossiakoff
Journal:  Protein Sci       Date:  1998-04       Impact factor: 6.725

8.  Interferon gamma modulation of disease manifestation and the local antibody response to alphavirus encephalomyelitis.

Authors:  Victoria K Baxter; Diane E Griffin
Journal:  J Gen Virol       Date:  2016-09-22       Impact factor: 3.891

9.  Ligand-induced assembly and activation of the gamma interferon receptor in intact cells.

Authors:  E A Bach; J W Tanner; S Marsters; A Ashkenazi; M Aguet; A S Shaw; R D Schreiber
Journal:  Mol Cell Biol       Date:  1996-06       Impact factor: 4.272

10.  Matrix metalloproteinases inhibition promotes the polyfunctionality of human natural killer cells in therapeutic antibody-based anti-tumour immunotherapy.

Authors:  Q Zhou; A Gil-Krzewska; G Peruzzi; F Borrego
Journal:  Clin Exp Immunol       Date:  2013-07       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.